▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Defining comprehensive models of care for NAFLD Liver health specialists
NAFLD places a substantial burden on healthcare systems and receives little attention from public health authorities. Ambitious measures are needed to improve preparedness globally. Prof Lazarus, Spain, discusses how to establish care pathways tailored to meet patients needs but also that optimally use existing resources. Modifiable risks factors are particularly important in a comprehensive strategy.
View More ⏩
HCC in Patients with NAFLD/NASH
Prof Bugianesi, Italy, reviews a burning issue: hepatocellular carcinoma (HCC) in patients with NAFLD/ NASH. She reviews the epidemiology globally and impact on liver transplant. There are multiple risks factors for HCC in NASH patients such as obesity, type 2 diabetes (T2D), and the metabolic syndrome in general. For clinicians, she presents the main studies, the profiles of the patients particularly at risk and risk stratifications strategies.
View More ⏩
NASH and Quality of Life
Prof Schattenberg, Germany, reviews how NASH impacts quality of life. He presents the mechanisms underlying metabolic comorbidities in NASH and discusses the relevant NASH phenotypes.
View More ⏩
NASH is Part of a Multi-System Disorder
Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease.
View More ⏩
From number-one liver disease to multi-system disease: NASH, a major unmet clinical need
In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
View More ⏩
Imaging biomarkers in NAFLD: Could they avoid liver biopsy
There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
View More ⏩
Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany
As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.
View More ⏩
New insights into liver macrophages in NASH pathogenesis
Prof Tacke, Germany reviews the epidemiological challenge of NAFLD and NASH worldwide, especially with the obesity pandemic. He describes the clinical impact of inflammation and fibrosis in NAFLD and the role of macrophages. Finally, he discusses the possible therapeutic implications.
View More ⏩
Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1
Prof. Chris Byrne (UK) discusses NAFLD as a multisystem disease and how NAFLD is a risk factor for other extra hepatic diseases beyond the liver
View More ⏩
Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2
It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.
View More ⏩
Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩
Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Prof. Arun Sanyal (USA) talks about and explores phase 3 development in NASH as part of the PanNash initiative as well as drug development and so on
View More ⏩
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES